Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep584 | Pituitary and Neuroendocrinology | ECE2020

A novel mechanism regulating dopamine receptor type 2 (DRD2) signal transduction in PRL- and ACTH-secreting pituitary tumoral cells: The role of cAMP/PKA-induced filamin A (FLNA) phosphorylation in the control of responsiveness to DRD2 agonist

Mangili Federica , Treppiedi Donatella , Catalano Rosa , Giardino Elena , Arosio Maura , Spada Anna , Mantovani Giovanna , Peverelli Erika

The actin binding protein filamin A (FLNA) is required for somatostatin receptor 2 (SST2) and dopamine receptor 2 (DRD2) expression, intracellular localization and signaling in GH- and PRL-secreting pituitary tumors, respectively, playing a role in tumor responsiveness to somatostatin analogs and dopaminergic drugs. FLNA functions are tightly regulated by several mechanisms, including FLNA phosphorylation. It has recently been shown that in GH-secreting pituitary tumors FLNA p...

ea0032p827 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

cAMP exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A and exchange proteins directly activated by cAMP

Vitali Eleonora , Peverelli Erika , Mantovani Giovanna , Giardino Elena , Lania Andrea G. , Beck-Peccoz Paolo , Spada Anna

cAMP is implicated in the inhibition or stimulation of proliferation depending on cell type. The activation of cAMP–PKA pathway generates proliferative signals in GH-secreting adenomas whereas this effect is not present, or even opposite, in non-functioning pituitary cells (NFPA). Although cAMP effects were initially attributed to PKA activation, recently the discovery of two cAMP-activated guanine nucleotide exchange factors (Epac1,2) was proposed as a novel mechanism fo...

ea0022p720 | Signal transduction | ECE2010

Role of filamin-A in the regulation of dopamine D2 receptor localization and signaling in a lactotroph cell model

Mantovani Giovanna , Peverelli Erika , Ferrero Stefano , Vitali Eleonora , Beck-Peccoz Paolo , Spada Anna , Lania Andrea

Dopamine agonists (DA) inhibit prolactin (PRL) secretion and expression on the pituitary lactotrophs by binding dopamine D2 receptor. Prolactinomas are the most common secreting pituitary adenomas, and DA are the first choice for their treatment because they reduce PRL levels and tumor size. However, a subset of patients is resistant to DA. The mechanisms involved in DA resistance are not fully understood, although decreased expression of D2 receptor or altered signal transduc...

ea0020p585 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Genetic alterations of phosphodiesterase 11A (PDE11A) in acromegalic patients

Peverelli Erika , Ermetici Federica , Filopanti Marcello , Lania Andrea , Ferrero Stefano , Beck-Peccoz Paolo , Spada Anna

Background: Aberrant cAMP signalling is involved in the pathogenesis of somatotropinomas. Recently, variants of phosphodiesterase type 11A (PDE11A) gene have been described in patients with adrenocortical tumors. Aim of the study was to investigate the presence of these variants in patients with somatotropinomas.Subjects and methods: Germ-line DNA of 78 acromegalic patients was screened for known genetic variants of PDE11A by direct sequencing or restric...

ea0016p130 | Clinical cases | ECE2008

A fetus affected with a complete androgen insensitivity syndrome due to a novel mutation of AR and persistent Mullerian structures

Vainicher Cristina Eller , Muzza Marina , Gaetti Luigi , Fugazzola Laura , Bulfamante Gaetano , Spada Anna Maria

Complete androgen insensitivity syndrome (CAIS) is a rare X-linked disorder caused by androgen receptor gene (AR) mutations that result in complete impairment of genital virilisation. Usually CAIS patients, who have normal production of AMH by Sertoli Cells, do not show Mullerian derivatives, although the persistence of Mullerian duct derivatives up to now have been described in nine cases.Here, we report the case of a fetus aborted at 20 weeks for genit...

ea0016p658 | Signal transduction | ECE2008

G protein coupling and adenylyl cyclase inhibition are mediated by the DRY motif in the second intracellular domain of the SST5 receptor

Peverelli Erika , Lania Andrea , Mantovani Giovanna , Bondioni Sara , Beck-Peccoz Paolo , Spada Anna

Somatostatin exerts inhibitory effects on hormone secretion and cell proliferation by interacting with five different receptors (SST1–SST5) linked to effector systems via G proteins. The receptor structural domains mediating these effects have not been identified. Since SS is the hypothalamic peptide that physiologically inhibits GH secretion, aim of this study was to investigate the molecular determinants mediating the interaction of the human SST5 with G proteins and su...

ea0016p693 | Thyroid | ECE2008

Effects of 8-Cl-cAMP on growth and apoptotic process in poorly differentiated thyroid cancer cell lines

Lucchi Simona , de Filippis Tiziana , Calebiro Davide , Porazzi Patrizia , Spada Anna , Persani Luca

Tools that are highly effective in the treatment of differentiated thyroid cancer (DTC) loose their therapeutic potentials in poorly differentiated tumors. The synthetic analog 8-Cl-cAMP has been known to have an antiproliferative effect in a variety of cancer cells and is tested as antineoplastic agent in clinical trials. The signaling mechanisms that govern the 8-Cl-cAMP-induced growth inhibition are still uncertain and data in thyroid neoplasia are lacking. Therefore, we te...

ea0014oc2.3 | Bone &amp; calcium metabolism | ECE2007

Clinical and biochemical differences in patients affected with sporadic and type 1 multiple endocrine neoplasia (MEN) related primary hyperparathyroidism

Eller-Vainicher Cristina , Massironi Sara , Peracchi Maddalena , Persani Luca , Beck-Peccoz Paolo , Spada Anna , Corbetta Sabrina

Primary hyperparathyroidism (PHPT) may occur sporadically or within MEN syndromes. It is classically thought that PHPT in MEN occurs at earlier ages than sporadic PHPT without significant differences in clinical and biochemical presentation. The aim of the study was to compare clinical and biochemical parameters between sporadic PHPT and MEN1 patients. The study included 41 genetically diagnosed MEN1 patients (14M, 27F) and 88 sporadic PHPT patients (24M, 64F) matched for age ...

ea0014oc4.4 | Neuroendocriology basis | ECE2007

Is there a role for dopamine D2 receptor gene polymorphisms in determining cabergoline sensitivity in prolactin-secreting pituitary adenomas?

Filopanti Marcello , Barbieri Anna Maria , Angioni Rita , Lania Andrea , Mantovani Giovanna , Spada Anna , Beck-Peccoz Paolo

Dopamine agonist cabergoline (CB) is the first-choice treatment in prolactin-secreting adenomas (PRL-omas). It is effective in reducing PRL secretion and tumour size in about 90% of patients by binding dopamine D2 receptor (DRD2). Although no mutations in DRD2 were found, it has been reported that several polymorphisms of this locus associate with alcoholism and schizophrenia, diseases in which dopaminergic system plays an important role. To assess the possible asso...

ea0014p532 | (1) | ECE2007

Growth hormone deficiency and recombinant hGH (rhGH) replacement in children with idiopathic isolated GH deficiency: effects on the hypothalamus-pituitary-adrenal axis

Bergamaschi Silvia , Giavoli Claudia , Ferrante Emanuele , Rusconi Roberto , Lania Andrea G , Spada Anna , Beck-Peccoz Paolo

Cortisol and cortisone are interconverted by type 1 and type 2 11ßhydroxysteroid dehydrogenase (11ßHSD) isoenzymes. The type 1 isoenzyme is a widely expressed reductase that converts cortisone to cortisol regulating glucocorticoid tissue exposure. Its activity is inhibited by GH and IGF-I, being increased in GH deficiency (GHD) and decreased in acromegaly. In our experience rhGH therapy unmasked a central hypoadrenal state in adults with organic GHD, likely by normal...